Daily Cardiology Research Analysis
Analyzed 254 papers and selected 3 impactful papers.
Summary
Three rigorously conducted randomized trials signal potential shifts in cardiovascular practice: device-based left atrial appendage closure matched NOACs for major events while reducing non-procedural bleeding; angiography-derived FFR safely substituted wire-based physiology for PCI guidance; and ultrasound-facilitated catheter-directed fibrinolysis reduced early clinical deterioration in intermediate-risk pulmonary embolism without excess bleeding. Together, these studies favor simplified, safer, and more individualized interventional strategies.
Research Themes
- Device-based stroke prevention in atrial fibrillation
- Simplifying coronary physiology to guide PCI
- Catheter-directed therapies for intermediate-risk pulmonary embolism
Selected Articles
1. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation.
In a 3,000-patient international randomized trial of anticoagulation-eligible atrial fibrillation, device-based left atrial appendage closure was noninferior to NOACs for cardiovascular death, stroke, or systemic embolism at 3 years and superior for reducing non–procedure-related bleeding. These findings expand the potential role of LAA closure beyond patients intolerant to anticoagulation.
Impact: First large RCT to show that LAA closure can match NOAC efficacy while reducing bleeding in anticoagulation-eligible AF patients, potentially redefining stroke prevention strategies.
Clinical Implications: LAA closure may be considered as an alternative to long-term NOAC therapy in AF patients eligible for anticoagulation, particularly for those at elevated bleeding risk or with adherence concerns, pending guideline updates and shared decision-making.
Key Findings
- In 3,000 randomized AF patients eligible for anticoagulation, LAA closure was noninferior to NOACs for the composite of cardiovascular death, stroke, or systemic embolism at 3 years.
- LAA closure was superior to NOAC therapy for the safety endpoint of non–procedure-related bleeding.
- Randomization achieved balanced baseline characteristics (mean age 71.7 years; 31.9% women).
Methodological Strengths
- Large-scale, prospective, international randomized design with prespecified noninferiority and superiority testing
- Clinically meaningful composite efficacy endpoint and bleeding-focused safety endpoint
Limitations
- Abstract text truncation limits access to detailed subgroup and procedural complication data
- Longer-term durability beyond 3 years and device-specific complications require continued follow-up
Future Directions: Define patient subgroups with net clinical benefit, evaluate cost-effectiveness, and integrate LAA closure into shared decision-making frameworks and guideline updates.
BACKGROUND: For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are unsuitable candidates for long-term anticoagulation, but its role in patients who are eligible for anticoagulants has not been established. METHODS: In this ongoing, prospective, international, randomized trial involving patients with atrial fibrillation who were suitable candidates for anticoagulation, we randomly assigned patients in a 1:1 ratio to receive either device-based left atrial appendage closure (device group) or non-vitamin K antagonist oral anticoagulant (NOAC) therapy (anticoagulation group). The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for noninferiority (noninferiority margin, 4.8 percentage points) after 3 years of follow-up. The primary safety end point, non-procedure-related bleeding, was tested for superiority. RESULTS: Of the 3000 patients who underwent randomization, 1499 were assigned to the device group and 1501 to the anticoagulation group. The mean (±SD) age of the patients was 71.7±7.5 years, 31.9% of the patients were women, and the mean CHA
2. Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism.
Among 544 patients with intermediate-risk pulmonary embolism, ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation reduced the 7-day composite of PE-related death, cardiopulmonary decompensation, or symptomatic recurrence versus anticoagulation alone (RR 0.39) without increasing major bleeding or intracranial hemorrhage. The benefit was primarily due to fewer episodes of cardiopulmonary decompensation.
Impact: Provides randomized evidence that a standardized catheter-directed reperfusion strategy improves early clinical outcomes in intermediate-risk PE, addressing a major gap in management.
Clinical Implications: For selected intermediate-risk PE with RV dysfunction and biomarker elevation, ultrasound-assisted catheter-directed fibrinolysis may be considered to prevent early decompensation when bleeding risk is acceptable, with multidisciplinary PE response team input.
Key Findings
- Primary 7-day composite endpoint occurred in 4.0% with ultrasound-assisted catheter thrombolysis vs 10.3% with anticoagulation alone (RR 0.39; P=0.005).
- No intracranial hemorrhage was observed; major bleeding did not differ at 7 or 30 days.
- Benefit was driven by reduced cardiopulmonary decompensation/collapse.
Methodological Strengths
- Multinational randomized design with blinded outcome adjudication
- Prespecified inclusion criteria standardizing intermediate-risk PE (RV/LV ratio and troponin) and cardiorespiratory distress
Limitations
- Primary endpoint focuses on 7-day outcomes; longer-term clinical benefits (e.g., CTEPH prevention) were not primary targets
- Trial not powered for rare bleeding complications; external generalizability will depend on operator expertise and protocol adherence
Future Directions: Assess durability of benefit, quality of life, right ventricular recovery, and CTEPH incidence, and refine patient selection with imaging and biomarkers.
BACKGROUND: Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain. METHODS: We conducted a multinational, adaptive-design trial with blinded outcome adjudication. Patients with intermediate-risk pulmonary embolism (with a ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter of ≥1.0 and an elevated troponin level) were eligible if they had at least two indicators of cardiorespiratory distress (systolic blood pressure of ≤110 mm Hg, a heart rate of ≥100 beats per minute, or a respiratory rate of >20 breaths per minute). Patients were randomly assigned to undergo ultrasound-facilitated, catheter-directed fibrinolysis with alteplase plus anticoagulation (the intervention group) or anticoagulation alone (the control group) according to prespecified treatment protocols. The primary outcome was a composite of pulmonary embolism-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days. RESULTS: The intention-to-treat population comprised 544 patients: 273 in the intervention group and 271 in the control group. The mean (±SD) age was 58.2±13.5 years, and 42.6% of the patients were women. A primary-outcome event occurred in 11 patients (4.0%; 95% confidence interval [CI], 2.3 to 7.1) in the intervention group and 28 (10.3%; 95% CI, 7.2 to 14.5) in the control group (relative risk, 0.39; 95% CI, 0.20 to 0.77; P = 0.005). The effect was driven primarily by a lower risk of cardiorespiratory decompensation or collapse in the intervention group. Major bleeding occurred within 7 days after randomization in 11 patients (4.1%) in the intervention group and 6 (2.2%) in the control group (P = 0.32); major bleeding occurred within 30 days in 11 patients (4.1%) and 8 patients (3.0%), respectively (P = 0.64). No substantial between-group differences in the incidence of other serious adverse events were observed up to 30 days after randomization; no intracranial hemorrhage occurred. CONCLUSIONS: In patients with acute, intermediate-risk pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis plus anticoagulation led to a lower risk of the composite of pulmonary embolism-related death, cardiopulmonary decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days than anticoagulation alone. (Funded by Boston Scientific; HI-PEITHO ClinicalTrials.gov number, NCT04790370.).
3. Angiography-Derived Fractional Flow Reserve to Guide PCI.
In 1,930 patients with intermediate coronary lesions, an angiography-only physiologic strategy (FFRangio) was noninferior to pressure-wire–guided assessment for the 1-year composite of death, MI, or unplanned revascularization, with similar safety. This outcome trial supports wider adoption of angiography-derived physiology to guide PCI.
Impact: First international outcomes RCT to demonstrate that angiography-derived FFR can safely substitute wire-based physiology without compromising clinical endpoints, lowering barriers to physiology-guided PCI.
Clinical Implications: Cath labs may implement FFRangio to increase physiologic guidance use, reduce procedure time/device needs, and maintain outcomes, especially when wire passage is risky or vasodilators are contraindicated.
Key Findings
- Primary composite endpoint at 1 year: 6.9% with FFRangio vs 7.1% with pressure-wire FFR (HR 0.98; P<0.001 for noninferiority).
- No differences in bleeding, acute kidney injury, or procedure-related adverse events.
- Randomization balanced demographics (mean age 68.4 years; 25% women).
Methodological Strengths
- International randomized noninferiority design with clinically relevant composite endpoint
- Adequate sample size and safety assessment including bleeding and AKI
Limitations
- Open-label procedural assignment may introduce operator behavior differences, though endpoints were objective
- Generalizability may vary by image quality and center expertise with FFRangio software
Future Directions: Evaluate workflow, cost-effectiveness, and outcomes in complex anatomy and acute coronary syndromes; define hybrid strategies combining angiography- and wire-based physiology.
BACKGROUND: Assessing intermediate coronary lesions with an intracoronary pressure wire improves clinical outcomes in patients undergoing cardiac catheterization and percutaneous coronary intervention (PCI). However, clinical use of pressure-wire-based physiological assessment remains low. Measurement of fractional flow reserve (FFR) derived from coronary angiographic images alone correlates well with pressure-wire-based FFR measurements and may simplify procedures, but its effect on clinical outcomes is unknown. METHODS: In this international noninferiority trial, we randomly assigned patients undergoing coronary angiography who were found to have at least one intermediate coronary stenosis to physiological assessment with measurements derived from angiographic images (FFRangio) or with pressure-wire-based measurements. The primary end point was a composite of death, myocardial infarction, or unplanned, clinically indicated coronary revascularization at 1 year. The noninferiority margin was 3.5 percentage points. RESULTS: A total of 1930 patients were randomly assigned to physiological assessment with FFRangio (FFRangio group; 965 patients) or a pressure-wire-based approach (pressure-wire group; 965 patients). The mean age of the patients was 68.4 years, and 25.0% of the patients were women. At 1 year, a primary end-point event had occurred in 64 patients (Kaplan-Meier estimate, 6.9%) in the FFRangio group and 65 patients (Kaplan-Meier estimate, 7.1%) in the pressure-wire group (hazard ratio, 0.98; 95% confidence interval, 0.70 to 1.39; difference, -0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval, 2.1 percentage points; P<0.001 for noninferiority). There were no apparent differences between the groups with respect to the incidence of bleeding, acute kidney injury, or procedure-related adverse events. CONCLUSIONS: Among patients with intermediate coronary-artery lesions undergoing physiological assessment in the cardiac catheterization laboratory, an angiography-guided strategy involving FFRangio was noninferior to a pressure-wire-guided strategy with respect to a composite end point of death, myocardial infarction, or unplanned clinically indicated coronary revascularization at 1 year. (Funded by CathWorks; ALL-RISE ClinicalTrials.gov number, NCT05893498.).